A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
Public ClinicalTrials.gov record NCT00040677. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Efficacy and Safety of ICA-17043 With or Without Hydroxyurea Therapy in Patients With Sickle Cell Anemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled cells, an improvement in anemia, a reduction in painful crises, and ultimately, less end-organ disease is anticipated.
Study identification
- NCT ID
- NCT00040677
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2002 (Type not available)
- Primary completion
- Nov 2003 (Actual)
- Completion
- Jan 2004 (Actual)
- Last update posted
- Jul 18, 2011
2002 – 2004
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Birmingham | Alabama | — | — |
| Study Site | Oakland | California | — | — |
| Study Site | San Francisco | California | — | — |
| Study Site | Washington D.C. | District of Columbia | — | — |
| Study Site | Augusta | Georgia | — | — |
| Study Site | Chicago | Illinois | — | — |
| Study Site | Baltimore | Maryland | — | — |
| Study Site | Boston | Massachusetts | — | — |
| Study Site | Detroit | Michigan | — | — |
| Study Site | Jackson | Mississippi | — | — |
| Study Site | Brooklyn | New York | — | — |
| Study Site | New York | New York | — | — |
| Study Site | Chapel Hill | North Carolina | — | — |
| Study Site | Durham | North Carolina | — | — |
| Study Site | Philadelphia | Pennsylvania | — | — |
| Study Site | Pittsburgh | Pennsylvania | — | — |
| Study Site | Nashville | Tennessee | — | — |
| Study Site | Houston | Texas | — | — |
| Study Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00040677, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2011 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00040677 live on ClinicalTrials.gov.